A Safety, Pharmacokinetics & Efficacy Study of MAU868 for the Treatment of

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02758288` - BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach
Completed	`NCT01624948` - Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients	Phase 4
Active, not recruiting	`NCT05026021` - Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
Recruiting	`NCT05511779` - Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation	Phase 2
Recruiting	`NCT05183490` - R-MVST Cells for Treatment of Viral Infections	Phase 1
Active, not recruiting	`NCT00684372` - BK Viremia After Renal Transplantation	N/A
Recruiting	`NCT06219616` - Prediction of BK Virus Reactivation in Kidney Transplant Recipient	N/A
Not yet recruiting	`NCT05264259` - New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Terminated	`NCT05305040` - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant	Phase 2/Phase 3
Completed	`NCT04605484` - Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia	Phase 2
Terminated	`NCT04390113` - Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)	Phase 3
Withdrawn	`NCT02313844` - Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)	Phase 1
Completed	`NCT03532971` - Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Recruiting	`NCT02479698` - Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus	Phase 2
Recruiting	`NCT05101213` - Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients	Phase 1
Completed	`NCT01789203` - Ciprofloxacin for Prevention of BK Infection	Phase 4
Completed	`NCT04693637` - Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant	Phase 2/Phase 3
Recruiting	`NCT05618275` - Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
Recruiting	`NCT04542733` - The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient	N/A
Recruiting	`NCT05042076` - BK With VST for Kidney Transplant Patients	Phase 1

NCT number	NCT04294472
Study type	Interventional
Source	Vera Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	August 5, 2020
Completion date	February 10, 2022

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms